Effectiveness of Care Bundle in Preventing Medical Adhesive-Related Skin Injury Due to Central Venous Catheter Fixation in Children
1 other identifier
interventional
91
1 country
2
Brief Summary
Skin injury due to the use of medical adhesives is a common but under recognized complication in children. To prevent central venous catheter-related complications, care interventions should be planned in such a way that they do not lead to medical adhesive-related skin injury. Systematic administration of preventive care interventions is needed to reduce skin injuries associated with medical adhesive used for central venous catheter fixation. The SECURE Care Bundle has been developed by researchers based on the latest evidence to prevent medical adhesive-related skin injuries associated with central venous catheter fixation in children.The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, correctly applying and removing medical adhesives and registering medical adhesive related skin injury. This study aims to evaluate the effectiveness of the SECURE Care Bundle in reducing MARSI incidence related to CVC fixation in pediatric patients and to examine its influence on the MARSI occurrence time. Hypotheses Null Hypothesis (H₀): There is no effect of the SECURE Care Bundle in preventing skin injuries related to central venous catheter (CVC) fixation in children. Hypothesis 1 (H₁): Children who receive the SECURE Care Bundle experience a lower incidence of medical adhesive-related skin injury due to CVC fixation compared to those who receive standard care. Hypothesis 2 (H₂): Children who receive the SECURE Care Bundle develop medical adhesive-related skin injury due to CVC fixation later than those who receive standard care. This quasi-experimental study follows a pre-test/post-test control group design and will be conducted in the Pediatric Cardiovascular Intensive Care Unit. A total of 92 pediatric patients will participate. Following informed consent, patients will be allocated into intervention (n=46) and control (n=46) groups. Data collection tools will include a descriptive information form, the Braden QD Scale, a skin observation form, and the SECURE Care Bundle checklist. The intervention group will receive the SECURE Care Bundle, and its effectiveness will be assessed by analyzing MARSI incidence and time to onset.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2024
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 5, 2023
CompletedFirst Posted
Study publicly available on registry
November 8, 2023
CompletedStudy Start
First participant enrolled
July 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2025
CompletedNovember 25, 2025
November 1, 2025
10 months
November 5, 2023
November 20, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of medical adhesive-related skin injury due to central venous catheter fixation
Incidence of medical adhesive-related skin injury due to central venous catheter fixation refers to the proportion of patients who develop medical adhesive-related skin injury (MARSI). This outcome will be assessed in both the pre-test and post-test groups, and the results will be compared to evaluate the effectiveness of the intervention.Three types of MARSI incidence rates will be calculated: (1)the rate per 100 patients, (2)the rate per 100 MAs, and (3)the rate per 1000 days of MA use. The formulas for calculating each incidence rate will be as follows: (1)incidence rate per 100 patients= number of MARSIs/number of patients × 100, (2)incidence rate per 100 MAs= number of MARSIs/number of MAs × 100, and (3)incidence rate per 1000 days of MA use= number of MARSIs/number of days of MA usage × 1000.
From Day 1 (postoperative admission to PCCU) to MARSI occurrence or discharge, up to 30 days
Secondary Outcomes (1)
MARSI occurrence time
From Day 1 (the day of CVC insertion and fixation) to the first occurrence of MARSI or end of treatment, up to 30 days
Study Arms (2)
SECURE Care Bundle
EXPERIMENTALThe SECURE Care Bundle has been developed by researchers based on the latest evidence to prevent medical adhesive-related skin injuries associated with central venous catheter fixation in children. The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, correctly applying and removing medical adhesives and registering medical adhesive related skin injury.
Standart Care
ACTIVE COMPARATORNo intervention will be applied to this group. No intervention will be applied to this group. The care provided in the clinic will continue to be provided in the same way.
Interventions
The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives including CHG dressing and silicone based remover.
It is applied in routine care in the clinic. There is no standardization and no procedure for checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives. Only CHG dressing is used for central venous catheter care.
Eligibility Criteria
You may qualify if:
- Patients aged 0 to 18 years.
- Underwent cardiovascular surgery and had a jugular central venous catheter (CVC) inserted.
- Admitted to the Pediatric Cardiovascular Intensive Care Unit (PCCU) in the postoperative period.
- Have a Braden QD Scale score of 12 or higher at admission.
- Parental informed consent obtained via a voluntary participation form.
You may not qualify if:
- Patients who had a central venous catheter inserted in another unit prior to cardiovascular surgery.
- Patients with pre-existing skin injury around the catheter site before insertion.
- Patients with a known history of dermatological disease.
- Patients with a known allergy to any of the products used in the study.
- Patients for whom catheter leakage occurs.
- Patients whose catheter is removed due to complications (e.g., infection, dislodgement, or other clinical reasons).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Istanbul University- Cerrahpaşa
Istanbul, Şisli, 34116, Turkey (Türkiye)
Istanbul University- Cerrahpaşa
Istanbul, Şişli, 34381, Turkey (Türkiye)
Related Publications (1)
Sensoy O, Caglar S. SECURE Care Bundle to Prevent Medical Adhesive-Related Skin Injury in Paediatric Central Venous Catheter Fixation: A Study Protocol. Nurs Crit Care. 2025 Nov;30(6):e70226. doi: 10.1111/nicc.70226.
PMID: 41193400DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Özlem Şensoy
İstanbul University-Cerrahpaşa
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 5, 2023
First Posted
November 8, 2023
Study Start
July 1, 2024
Primary Completion
April 30, 2025
Study Completion
April 30, 2025
Last Updated
November 25, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- The data will be become available upon request for three years.
- Access Criteria
- The data will become available upon request by contacting with principle investigator.
Study Protocol and Statistical Analysis Plan will be provided.